Gelesis Holdings, Inc. (NYSE:GLS – Get Rating) was the target of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 637,300 shares, a growth of 16.0% from the December 15th total of 549,200 shares. Approximately 3.1% of the company's stock are short sold. Based on an average daily trading volume, of 148,700 shares, the days-to-cover ratio is presently 4.3 days.

Insider Activity at Gelesis

In related news, Director Raju S. Kucherlapati purchased 92,000 shares of the stock in a transaction that occurred on Monday, November 21st. The stock was acquired at an average cost of $0.45 per share, with a total value of $41,400.00. Following the transaction, the director now owns 190,264 shares of the company's stock, valued at approximately $85,618.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Gelesis by 564.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,935,975 shares of the company's stock worth $3,171,000 after acquiring an additional 2,494,379 shares during the period. Vitruvian Partners LLP bought a new position in shares of Gelesis during the 3rd quarter worth $2,026,000. Neuberger Berman Group LLC bought a new position in shares of Gelesis during the 1st quarter worth $5,276,000. BlackRock Inc. grew its stake in shares of Gelesis by 33.5% during the 3rd quarter. BlackRock Inc. now owns 774,052 shares of the company's stock worth $835,000 after acquiring an additional 194,043 shares during the period. Finally, Northeast Financial Consultants Inc grew its stake in shares of Gelesis by 1,480.1% during the 3rd quarter. Northeast Financial Consultants Inc now owns 395,035 shares of the company's stock worth $427,000 after acquiring an additional 370,035 shares during the period. Institutional investors own 16.71% of the company's stock.

Gelesis Price Performance

Gelesis (NYSE:GLS – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. The business had revenue of $6.65 million during the quarter.

About Gelesis

(Get Rating)

Gelesis Holdings Inc, a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.

Featured Articles

• Get a free copy of the StockNews.com research report on Gelesis (GLS)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Gelesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelesis and related companies with MarketBeat.com's FREE daily email newsletter.